Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

MLA

McLendon, Roger E., et al. “Tumor Resection Cavity Administered Iodine-131-Labeled Antitenascin 81C6 Radioimmunotherapy in Patients with Malignant Glioma: Neuropathology Aspects.” Nuclear Medicine and Biology, vol. 34, no. 4, May 2007, pp. 405–13. EBSCOhost, https://doi.org/10.1016/j.nucmedbio.2007.01.009.

APA

McLendon, R. E., Akabani, G., Friedman, H. S., Reardon, D. A., Cleveland, L., Cokgor, I., Herndon, J. E., 2nd, Wikstrand, C., Boulton, S. T., Friedman, A. H., Bigner, D. D., & Zalutsky, M. R. (2007). Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology, 34(4), 405–413. https://doi.org/10.1016/j.nucmedbio.2007.01.009

Chicago

McLendon, Roger E, Gamal Akabani, Henry S Friedman, David A Reardon, Linda Cleveland, Ilkcan Cokgor, James E Herndon 2nd, et al. 2007. “Tumor Resection Cavity Administered Iodine-131-Labeled Antitenascin 81C6 Radioimmunotherapy in Patients with Malignant Glioma: Neuropathology Aspects.” Nuclear Medicine and Biology 34 (4): 405–13. doi:10.1016/j.nucmedbio.2007.01.009.